Donate For Public and Patients Store Search

S026 - Vascular Anomalies Symposium: Classification, Clinical Challenges, and Management Update

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Implement the recent AAP guidelines of care for Infantile hemangioma. Assess and implement the best treatment for ulcerated infantile hemangioma.
  • Describe emerging targeted therapy for vascular anomalies.
  • Compare and contrast benefits of topical beta-blocker vs oral beta-blocker therapy for infantile hemangioma.

Description

This session features leading experts in the field of vascular anomalies and will focus on recent enhancements to guidelines of care, therapeutic pearls, and emerging targeted therapy (precision medicine) in this dynamic field.

Disclosures

  • Baselga, Eulalia, MD: Almirall – SP(H); Cytovation – C(Fees); Ferrer – C(H), SP(Fees); Martiderm – SP(Fees); Novartis – O(OB), SP(Fees); Pierre Fabre Dermatologie – I(H), SP(Fees); Sanofi/Regeneron – C(Fees); venthera – F(SO);
  • Drolet, Beth Ann, MD: Pierre Fabre Dermatologie – O(Grants/Research Funding); Venthera – C(Fees);
  • Frieden, Ilona J., MD: Pfizer Inc. – Data Safety Monitoring Board(Fees); Venthera – A(H);
  • Garzon, Maria Cecilia, MD: Astellas Pharma US, Inc – I(NC); NIH – I(Grants/Research Funding);
  • Puttgen, Katherine B., MD: Anacor Pharmaceuticals, Inc. – A(H); Pierre Fabre Dermatologie – A(H);
Schedule
Saturday, March 2
1:00 PM
Dr. Frieden / American Academy of Pediatrics Consensus Guidelines for infantile hemangioma
1:35 PM
Dr. Puttgen / Propranolol guidelines updated; Prescreening and initiation of oral propranolol for infantile hemangioma
1:55 PM
Dr. Garzon / Propranolol for infantile hemangioma; Rebound growth and poor responders
2:20 PM
Dr. Drolet / Topical beta-blocker therapy for infantile hemangioma
2:35 PM
Dr. Baselga / Ulcerated infantile hemangioma in the era of beta-blocker therapy
3:05 PM
Dr. Drolet and Dr. Baselga / Vascular anomalies associated with activation of the PI3K pathway; Paving the road to precision medicine
3:30 PM
Dr. Adams / Repurposing cancer drugs for vascular anomalies: MEK and AKT inhibitors
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 140A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Beth Ann Drolet, MD, FAAD
Speakers
  • Eulalia Baselga, MD
  • Ilona J. Frieden, MD, FAAD - Handout
  • Katherine B. Puttgen, MD, FAAD
  • Maria Cecilia Garzon, MD, FAAD - Handout